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Background: Mesenchymal stem cells (MSC) are multipotent progenitor cells characterized by their ability to both
self-renew and differentiate into tissues of mesodermal origin. The plasticity or transdifferentiation potential of
MSC is not limited to mesodermal derivatives, since under appropriate cell culture conditions and stimulation by
bioactive factors, MSC have also been differentiated into endodermal (hepatocytes) and neuroectodermal (neurons)
cells. The potential of MSC for hepatogenic and neurogenic differentiation has been well documented in different
animal models; however, few reports are currently available on large animal models. In the present study we sought to
characterize the hepatogenic and neurogenic differentiation and multipotent potential of bovine MSC (bMSC) isolated
from bone marrow (BM) of abattoir-derived fetuses.
Results: Plastic-adherent bMSC isolated from fetal BM maintained a fibroblast-like morphology under monolayer
culture conditions. Flow cytometric analysis demonstrated that bMSC populations were positive for MSC markers
CD29 and CD73 and pluripotency markers OCT4 and NANOG; whereas, were negative for hematopoietic markers CD34
and CD45. Levels of mRNA of hepatic genes α-fetoprotein (AFP), albumin (ALB), alpha1 antitrypsin (α1AT), connexin 32
(CNX32), tyrosine aminotransferase (TAT) and cytochrome P450 (CYP3A4) were up-regulated in bMSC during a 28-Day
period of hepatogenic differentiation. Functional analyses in differentiated bMSC cultures evidenced an increase (P < 0.05)
in albumin and urea production and glycogen storage. bMSC cultured under neurogenic conditions expressed NESTIN
and MAP2 proteins at 24 h of culture; whereas, at 144 h also expressed TRKA and PrPC. Levels of MAP2 and TRKA mRNA
were up-regulated at the end of the differentiation period. Conversely, bMSC expressed lower levels of NANOG mRNA
during both hepatogenic and neurogenic differentiation processes.
Conclusion: The expression patterns of linage-specific markers and the production of functional metabolites support the
potential for hepatogenic and neurogenic differentiation of bMSC isolated from BM of abattoir-derived fetuses.
The simplicity of isolation and the potential to differentiate into a wide variety of cell lineages lays the foundation for
bMSC as an interesting alternative for investigation in MSC biology and eventual applications for regenerative therapy in
veterinary medicine.
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Mesenchymal stem cells (MSC) are multipotent progeni-
tor cells characterized by their ability to both self-renew
and differentiate into tissues of mesodermal origin (osteo-
blasts, adipocytes, chondrocytes and myocytes) [1]. Despite
several tissues have been explored for the isolation of MSC
including adipose, umbilical and placental; animal bone
marrow (BM) is the most common source of MSC for clin-
ical and research uses. MSC are directly isolated from bone
marrow aspirates based on their ability to adhere to plastic
when plated in monolayer culture and thereafter replicate
ex vivo to form a phenotypically homogeneous population
of cells [2]. Plastic adherence under standard culture con-
ditions is one of the criteria for defining MSC by the
International Society for Cellular Therapy (ISCT). Other
requirements include trilineage differentiation potential
and expression of MSC surface antigens markers CD105
(endoglin), CD73 (ecto-5’-nucleotidase) and CD90 (Thy-1),
and lack of expression of hematopoietic markers CD45
(protein tyrosine phosphatase, receptor type, C), CD34
(CD34 molecule) and CD14 (CD14 molecule) [3].
Despite the wide relevance of the bovine experimental
model in both in vivo and in vitro experiments, limited
information regarding bovine MSC (bMSC) is available.
Similarities in organ size and physiology with humans
and a longer life span in comparison with traditional la-
boratory animal models support the use of large animal
models for long-term experiments in regenerative medi-
cine [4,5]. Development of a bMSC model would be in-
valuable for testing the efficiency and safety of these
cells for future cell therapies and for the creation of
human disease models. Moreover, cattle can give ad-
vantages for clinical applications of MSC to human
and veterinary medicine especially in musculoskeletal
disorders [6-8].
Previous studies reported isolation and mesenchymal
differentiation of bMSC from calf BM [7,9] and bovine
umbilical cord [10,11]. We have reported the isolation
and mesenchymal multilineage differentiation of bMSC
derived from BM of abattoir-derived bovine fetuses [12].
Studies performed on human MSC isolated from fetal
BM have shown that these cells possess higher proliferative
capacity, trilineage differentiation potential and lower im-
munogenicity compared to MSC from umbilical cord, adult
BM or adipose tissue [13]. Moreover, human fetal MSC
isolated from BM had higher proliferative and osteogenic
capacity than MSC derived from other ontological and ana-
tomical origins, suggesting that they are superior candidates
for bone tissue engineering [13,14]. The simplicity of isola-
tion and the potential to differentiate into several cell types
lays the foundation for fetal bMSC, as an interesting source
for investigation of stem cell biology. Moreover, the devel-
opment of large animal experimental models including cat-
tle may open alternative strategies for investigating MSCphysiology and eventual applications for regenerative ther-
apy in human and veterinary medicine. As an example, re-
cently it has been proposed the potential application of
various stem/progenitor cells including mammary stem
cells for the repair of post-mastitis structural defects in
dairy animals [15,16].
The plasticity or transdifferentiation potential of MSC
is not limited to mesenchymal derivatives, since under
appropriate cell culture conditions and stimulation by
certain exogenous or endogenous bioactive factors, MSC
have also been differentiated into endodermal (hepato-
cytes) and neuroectodermal (neurons) cells [17,18]. The
potential for hepatogenic differentiation of MSC has been
evaluated by measuring the expression of endodermal or
hepatocyte markers including α-fetoprotein (AFP), albumin
(ALB), alpha1 antitrypsin (α1AT), connexin 32 (CNX32),
tyrosine aminotransferase (TAT) and cytochrome P450
(CYP3A4) [19]. The functional capacity has also been
assessed by determining urea production and glycogen stor-
age [18]. Moreover, a large body of evidence has established
the neural differentiation potential of MSC derived from
BM. Treatment of BM-MSC with different molecules and
growth factors induced rapid morphological changes that
are typical of neural cells together with the expression of
neural markers such as neuroepithelial stem cell intermedi-
ate filament (NESTIN), microtubule associated protein 2
(MAP2), nerve growth factor (NGF), tropomyosin-related
kinase A (TRKA) and cellular prion protein (PrPC) [20-22].
Thus, the potential for isolation and differentiation into
hepatocyte- and neuron-like cells, as well as their capacity
for transplantation, suggests that MSC represent an attract-
ive therapeutic candidate for treating degenerative diseases.
In the present study, we used abattoir-derived bovine
fetuses as an available and plentiful source of BM with
the aim to obtain an abundant supply of bMSC for
in vitro differentiation experiments. Our main objective
was to characterize the hepatogenic and neurogenic dif-
ferentiation potential of bMSC isolated from abattoir-
derived bovine fetuses by gene expression and functional
analyses.
Results
Mesenchymal cell surface marker and multipotent profile
of BM-bMSC from abattoir-derived fetuses
Fetal bMSC were isolated from BM based on the capacity
for plastic attachment under standard culture conditions
that included DMEM media supplemented with 10% FBS.
After 5 to 6 days of culture, colonies of fibroblast-like cells
were visualized attached to plastic culture flasks. Isolated
cells were cultured for several weeks in monolayer and used
for differentiation experiments after 4 to 5 passages. Flow
cytometric analysis of bMSC demonstrated that higher
(P < 0.05) percentage of these cells were positive for MSC
markers CD29 (76.3%) and CD73 (96.8%) and pluripotency
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In comparison, a higher (P < 0.05) percentage of cells
was negative for hematopoietic markers CD34 and
CD45 (93.4% and 95.6%, respectively).Gene expression profile in bMSC during hepatogenic
differentiation
Culture of bMSC in monolayer under hepatogenic condi-
tions induced polygonal cell morphology and formation of
cell aggregates at Day 28 of culture (Figure 2A). AFP pro-
tein was immunodetected in differentiated bMSC at Day
28 of culture (Figure 2B). At this stage, levels of AFP, ALB,
α1AT, CNX32, TAT mRNA levels were up-regulated
(P < 0.05) in differentiated bMSC (60.6-, 331.4-, 166.8-,
201.1-, 446.5-fold relative to Day 0, respectively) (Figure 2B).
Levels of CYP3A4 mRNA were higher (P < 0.05) in differ-
entiated compared to control bMSC from Day 7 until Day
28 of culture (154.7- and 104.4-fold relative to Day 0 vs. 69-
and 34-fold in untreated controls). In contrast, NANOG
mRNA levels were lower (P < 0.05) in differentiated bMSC
at Days 14, 24 and 21 of culture (1.2-. 0.86- and 0.97-fold
relative to Day 0 vs. 8.6, 6.4- and 4.6-fold in untreated
controls).Functional characterization of bMSC during hepatogenic
differentiation
More intense PAS staining associated to stored glycogen
was observed in differentiated compared to control
bMSC at Day 28 of culture (Figure 3A). At Days 21
and 28 of differentiation, higher (P < 0.05) secretion of
albumin (494.1 and 1213 μg/mL vs. 88.2 and 232.9 μg/mL
in untreated controls) and urea concentration (7.3 andFigure 1 Flow cytometric analysis of bMSC isolated by plastic adhere
(P < 0.05) of bMSC (shaded region) was positive for MSC surface antigens C
Similarly, the majority of MSC expressed pluripotent genes OCT4 and NANO8.2 mg/dL vs. 4.7 and 5.6 mg/dL in untreated controls)
were detected in differentiated bMSC cultures (Figure 3B).Gene expression profile in bMSC during neurogenic
differentiation
Protocol 1 used for neurogenic differentiation induced
formation of compact and spherical cell bodies with
multiple extensions since 96 h of culture (Figure 4A).
No significant differences in mRNA levels of neural
markers NESTIN, MAP2, NGF and TRKA were detected
between bMSC cultured under differentiating and con-
trol conditions (Figure 4B). Protocol 2 induced cell body
retraction and formation of multiple and complex cell
extensions in differentiated bMSC since 96 h of culture
(Figure 5A). These cells expressed NESTIN and MAP2
proteins at 0 h of culture; whereas, at 144 h also
expressed TRKA and PrPC (Figure 5B and C). Differenti-
ated bMSC expressed higher (P < 0.05) levels of MAP2
mRNA (22.8-fold relative to Day 0 vs. 0.42-fold in
untreated controls) at 144 h of culture (Figure 5C).
Similarly, levels of TRKA mRNA were higher (P < 0.05)
in differentiated bMSC at 96 h and 144 h of culture
(51.4- and 111.2-fold relative to Day 0 vs. 23.1- and
31.3-fold in untreated controls). Conversely, differenti-
ated bMSC expressed lower (P < 0.05) mRNA levels of
NANOG at 96 h and 144 h of culture (16.3- and 17.4-
fold relative to Day 0 vs. 47.9- and 25.8-fold in
untreated controls). No significant differences were
detected for NESTIN, NGF and PrPC mRNA levels
between treated and untreated bMSC; however, both
cell populations expressed higher (P < 0.05) levels of
NESTIN at 24 h of culture.nce from BM of abattoir-derived fetuses. Higher percentage
D29, CD73 and negative for hematopoietic markers CD34 and CD45.
G. Open region in each panel represent the control.
Figure 2 (See legend on next page.)
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Figure 2 Hepatocyte and multipotent gene expression profile in bMSC under hepatogenic conditions during a 28-Day in vitro culture
period. (A) bMSC were isolated by plastic adherence from bovine fetal BM and cultured under hepatogenic or control conditions. Culture of fetal
bMSC under hepatogenic conditions stimulated cell replication at earlier stages and induced formation of polygonal cell morphology and cell
aggregates at Day 28 of culture. (B) AFP protein was immunodetected in cell aggregates in differentiated (DIF) but not in control (CON) bMSC
cultures at Day 28. AFP mRNA levels increased (P < 0.05) in differentiated bMSC at Day 28 of culture. Similarly, ALB, α1-AT, CNX32, and TAT and
mRNA levels increased (P < 0.05) in differentiated bMSC at Day 28 of culture. Levels of CYP3A4 mRNA were higher (P < 0.05) in differentiated
compared to control bMSC from Day 7 until Day 28 of culture. NANOG mRNA levels were lower (P < 0.05) in differentiated compared to control
bMSC from Day 14 to Day 28 of culture. (*) Superscripts represent significant (P < 0.05) differences between treatments and sampling days. Bar
scale: 500 μm.
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In the present study, bMSC were isolated from BM col-
lected from abattoir-derived fetuses based on the capacity
to adhere to plastic substrate under monolayer culture con-
ditions. These cells expressed MSC specific markers CD29
and CD73 and lacked expression of hematopoietic surface
markers CD34 and CD45. Little information is available
regarding expression of MSC surface markers in bMSC.
Analyses by flow cytometry in bMSC isolated from the
Wharton’s jelly detected high proportion of cells positive
for CD29, CD73, CD90 and CD105 and negative for
CD34 and CD45 [11]. Using Q-PCR, we reported a
similar MSC marker profile in bMSC isolated from BM
of abattoir-derived bovine fetuses [12]. Recently, these
results have been confirmed by immunofluorescence
and RT-PCR in bMSC isolated from fetal BM [23].
Thus, in vitro characterization presented in this study
and in previous reports including adherence to plastic
substrate, expression of mesenchymal markers and
differentiation into mesodermal lineages suggests that
bMSC isolated from fetal BM by plastic adherence
fulfill the minimal criteria for definition of MSC.
The 2-step sequential hepatogenic differentiation proto-
col used in our study included early (EGF), middle (HGF),
and late (OSM, dexamethasone, ITS and DMSO) differenti-
ation factors [24]. HGF is an endocrine or paracrine fac-
tor essential for liver development that promotes cell
survival and regeneration [25]. OSM is a member of the
interleukin-6 cytokine family that increases cell size of
hepatocytes and induces cell differentiation and forma-
tion of bile canaliculi [26]. The capacity to induce hep-
atocyte functions, albumin secretion and cytochrome
activity may be enhanced when OSM is combined with
DMSO [27]. Dexamethasone, a synthetic glucocorticoid
that induces hepatic gluconeogenesis, promotes the
expression of hepatocyte phenotype through the sup-
pression of cell division [28]. The hepatogenic differen-
tiation potential of fetal bMSC was evaluated using
quantitative and qualitative analyses. Spindle shape
and polygonal cell morphology observed at Day 28 in dif-
ferentiated bMSC was not typical hepatocyte-like morph-
ology described in previous studies. However, during
mesenchyme-to-hepatocyte differentiation, expression
of specific transcription factors of early endoderm,bipotential cells, and finally hepatocytes were up-regulated.
It is recognized that AFP and ALB are abundant proteins
synthesized from early fetal to adult mature hepatocytes
[29,30]. TAT and α1AT are liver-specific enzymes involved
in degradation of tyrosine and inhibition of proteases, and
are known to be late markers of the hepatocyte lineage
[31,32]. CNX32 is a major gap junction protein which ac-
count for the 90% of connexin proteins in the liver [33]. Ex-
pression of these genes at the latest stage of differentiation
indicates that prolonged exposure to hepatogenic factors is
required in order to trigger the mesenchymal-to-hepatic
transition. However, increasing levels of CYP3A4 mRNA
Day 7 of culture suggest that activation of catalytic enzymes
involved in the hepatic metabolism occurs at early stages of
hepatogenic differentiation [34]. Moreover, production of
albumin and urea at Days 21 and 28 of hepatogenic
differentiation demonstrate the acquisition of hepatocyte
metabolic activity in differentiated bMSC [35]. These re-
sults along with detection of glycogen storage indicate that
bMSC underwent transdifferentiation into the endodermic
hepatogenic lineage in agreement with the attainment of
the hepatocyte gene expression profile.
In order to investigate the ectodermal differentiation po-
tential, bMSC were induced toward neurogenic lineage
using a previously reported BME-based protocol [17].
bMSC morphology including formation of compact
cell bodies with multiple extensions along with expres-
sion of neural stem cell marker NESTIN and mature
neuron markers MAP2, NGF and TRKA, initially sug-
gested the acquisition of neural properties in treated
bMSC. However, absence of neural marker increment
in bMSC after treatment with a BME indicates that this
simple chemical neuronal induction protocol was not
able to induce neural differentiation. Previous studies
have reported that BME-based protocols may induce
neuronal phenotype in other cell types lacking any
stem cell characteristics (fibroblasts, HEK 293 and PC-
12 cells) [36,37]. This neuron-like appearance was as-
sociated to disruption of cytoskeleton after cell stress
due to toxic chemicals rather than cell differentiation.
A second protocol based on combination of growth
factor pretreatment and induction with previously re-
ported factors was assessed in fetal bMSC for neuro-
genic differentiation [38]. EGF-bFGF pretreatment have
Figure 3 (See legend on next page.)
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Figure 3 Functional hepatocyte characterization of bMSC under hepatogenic conditions during a 28-Day in vitro culture period.
(A) More intense positive PAS staining was observed in differentiated (DIF) compared to control (CON) bMSC cultures. (B) Production of albumin
increased (P < 0.05) in differentiated bMSC cultures at Days 21 and 28 of hepatogenic differentiation. Similarly, levels of urea increased (P < 0.05)
in differentiated bMSC at Days 21 and 28 of hepatogenic differentiation. (*) Superscripts represent significant (P < 0.05) differences between
treatments. Bar scale: 500 μm.
Figure 4 Neural and multipotent gene expression profile in bMSC under differentiating conditions using neurogenic protocol 1.
(A) bMSC were isolated by plastic adherence from bovine fetal BM and cultured under neurogenic or control conditions. Culture of fetal bMSC
under neurogenic conditions induced formation of cell body retraction and formation of multiple and complex extensions since 24 h of culture.
(B) Analysis of Q-PCR detected mRNA levels of neural markers NESTIN, MAP2, NGF and TRKA in fetal bMSC cultured under control (CON) and differentiating
(DIF) conditions. No differences (P > 0.05) in mRNA levels were detected between control and differentiated cultures. (a,b) Superscripts represent significant
(P < 0.05) differences between sampling hour. Bar scale: 500 μm.
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Figure 5 Neural gene expression profile in bMSC under
differentiating conditions using neurogenic protocol 2.
(A) Culture of fetal bMSC under neurogenic conditions induced
formation of polygonal cell morphology and cell aggregates at Day 28
of culture. (B) At 24 h of culture, differentiated bMSC expressed both
NESTIN and MAP2 proteins; whereas, at 144 h of culture also expressed
TRKA and PrPC proteins. (C) MAP2 protein was immunodetected in cell
cytoplasm associated to the cytoskeleton. Levels of MAP2 mRNA were
up-regulated in differentiated (DIF) bMSC at 144 h of culture. In addition,
these cells expressed higher (P < 0.05) levels of TRKA mRNA at 96 and
144 h of culture compared to controls. No differences in mRNA levels
were detected for NESTIN, NGF and PrPC between differentiated and
control bMSC cultures. NANOG mRNA levels were lower (P < 0.05) in
differentiated compared to control bMSC from 96 h to 144 h of culture.
(*, a,b) Superscripts represent significant (P < 0.05) differences between
treatments and sampling days, respectively. Bar scale: 500 μm.
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vation of neural/neuronal gene expression pattern [39].
Thereafter, culture in differentiation medium containing
KCL, valproic acid, forskolin and hydrocortisone has
showed to induce neuronal morphological and immuno-
cytochemical changes in human and murine adipose-
derived stem cells [38]. In our study, morphology changes
in bMSC during culture were characterized by cell body
retraction and formation of multiple and complex cell ex-
tensions that were consistent with neuronal differentiation.
These cells expressed NESTIN and MAP2 at 24 h of
culture, in addition with TRKA and PrPC after 144 h of cul-
ture. The capacity of MSC to coexpress immature and ma-
ture neuronal or glial proteins has been previously
associated to the plasticity to differentiate in various tissues
[40,41]. In our study, immunodetection of NESTIN, MAP2,
TRKA and PrPC proteins, along with up-regulation of
MAP2 and TRKA mRNA in differentiated bMSC indicated
that these cells were induced toward neural linage. How-
ever, a functional assay will be required before concluding
that these cells have the potential to become neurons. Lack
of significant differences in NESTIN, NGF and PrPC mRNA
levels between bMSC treatments were probably due to re-
duced level of expression of these genes. Constituently ex-
pression of NESTIN and MAP2 in MSC cultured without
any previous induction, have been previously associated to
the presence of a multidifferentiated state, in which MSC
may retain a native potential for differentiation [42]. Previ-
ously, it have been reported that after in utero transplant-
ation of human MSC in sheep or systemic infusion in
baboons, MSC are found distributed in several tissues in-
cluding gastrointestinal, kidney, liver, and skin [43,44].
These studies support the hypothesis [42] that subpopula-
tions of MSC are in reality in a multidifferentiated state and
participate in vivo in the turnover and replacement of a
wide variety of tissues. Furthermore, these subpopulations
may also explain the expression of lineage-specific markers
in supposedly undifferentiated MSC populations. Although
expression of NESTIN has been associated to early
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including myogenic, endothelial and hepatic suggest that
this protein may not play a unique role in neurogenic dif-
ferentiation [45]. Considering the proposed role of PrPC in
neural differentiation of embryonic stem cells (ESC) [46]
and its participation in bovine spongiform encephalopathy
(BSE) [47], transdifferentiation of MSC into neural cells
could provide a valuable in vitro model for the study of
prion diseases. Using co-localization analyses in the neuro-
epithelium of bovine fetuses and an in vitro differentiating
ESC model, it has been shown that PrPC influences the dif-
ferentiation of NESTIN-expressing cell lineages, including
neural lineages [46]. These data provides clues of the com-
plex signaling pathways that mediate ESC neural differenti-
ation; however, further in vitro differentiation experiments
would be required in order to elucidate if this interactions
are similar in MSC.
The expression of pluripotent markers OCT4 and
NANOG was analyzed with the aim to evaluate the state
of multipotency in bMSC during mesenchymal differen-
tiation. OCT4 and NANOG regulate the maintenance of
pluripotent state in embryos and derived cells in most
mammalian species [48,49]. These transcription factors
had been proposed to play a similar role in adult stem cells
[50]. However, recent reports have indicated that NANOG
expression is associated to adaptation to in vitro cell growth
conditions in differentiating MSC [51,12]. In our study, the
patterns of expression of OCT4 and NANOG in undiffer-
entiated MSC support the potential participation of these
factors during the multipotent state. Moreover, our data
suggest that the multipotent capacity of bMSC is reduced
according to the acquisition of the hepatogenic phenotype
and functional activity.
Conclusions
The expression patterns of lineage-specific markers and
the production of functional metabolites demonstrate
the acquisition of hepatocyte and neuronal profiles in
bMSC after independent in vitro hepatogenic and neuro-
genic independent differentiations. The simplicity of iso-
lation and the potential to differentiate into several cell
types lays the foundation for BM MSC isolated from
abattoir-derived bovine fetuses, as an alternative source
of MSC for investigation of biology and eventual appli-
cations for regenerative therapy in veterinary medicine.
Methods
All procedures have been approved by the Bioethical
Committee of the National Commission for Scientific
and Technology Research (Fondecyt).
Isolation and culture of bMSC from fetal bone marrow
Bone marrow was aspirated from bovine fetuses (n = 10;
7–8 months of gestation) collected at a local abattoir.The marrow was drawn from femoral marrow cavity
into syringes containing high glucose Dulbecco’s Modi-
fied Eagle Medium (DMEM, Gibco, Grand Islands, NY,
USA) supplemented with 10% fetal bovine serum (FBS),
1000 U heparin, 100 U/mL penicillin and 100 μg/mL
streptomycin. Bone marrow samples were washed twice
with phosphate-buffered saline (PBS) and twice with
DMEM. Then cells were plated in DMEM (high glucose)
supplemented with 10% FBS, 100 U/mL penicillin, 100 μg/
mL streptomycin and 0.25 μg/mL amphotericin B. Cells
were incubated at 38°C in a humidified atmosphere con-
taining 5% CO2. Non-adherent cells were removed by
changing the culture medium after 4 days. Following the
initial 4 days, the medium was changed every 2–3 days.
After 4 to 5 passages, cells were gently harvested when 90%
confluent using 0.25% trypsin in 0.1% EDTA and used for
differentiation experiments.
Hepatogenic differentiation
Induction of hepatogenic differentiation was performed
using an adapted protocol from a previously published
report [24]. Cells (3×103/cm2) at passages 3 to 5 were
plated in T-25 culture dishes either in control or differ-
entiation medium. Control medium consisted of DMEM
(low glucose) supplemented with 5% FBS, 100 U/mL
penicillin, 100 μg/mL streptomycin and 0.25 μg/mL
amphotericin B. bMSC were cultured in control medium
for 1 week followed by culture in FBS-free control medium
for three weeks. Differentiation was induced by treating
bMSC with Step-1 differentiation medium consisting in
57.5% DMEM (low glucose) and 37.5% MCDB-201 (Sigma-
Aldrich, St. Louis, MO, USA) supplemented with 1x ITS
(BD Biosciences, San Jose, CA, USA), 1 nM dexametha-
sone, 0.1 mM ascorbic acid 2-phosphate (Sigma), 10 ng/mL
rhEGF (BD Biosciences), 100 μg/mL streptomycin, 100 U/
mL penicillin, 2.5 μg/mL amphotericin B and 5% FBS for 7
days. Thereafter, bMSC were treated with Step-2 differenti-
ation medium consisting in Step-1 differentiation medium
supplemented with 0.1% DMSO (Calbiochem, Darmstadt,
Germany), 10 ng/mL rhHGF (Sigma) and 10 ng/mL
rhOSM (Sigma) for 21 days. Medium change was per-
formed every other day and cell samples were obtained
from control and differentiation bMSC at Days 0, 7, 14
and 21 of culture and analyzed for β-ACTIN, AFP, ALB,
α1AT, CNX32, TAT, CYP3A4 and NANOG expression by
Q-PCR.
Neurogenic differentiation
Induction of neurogenic differentiation was performed
using adapted protocols from previously published re-
ports [17,38]. Cells (5×103/cm2) at passages 3 to 5 were
plated in T-25 culture dishes either in control or differ-
entiation medium. Control medium consisted of DMEM
(low glucose) supplemented with 100 U/mL penicillin,
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B. In protocol 1, bMSC were cultured in a pre-induction
medium consisting in DMEM (high glucose) supple-
mented with 20% FBS, 1 mM β-mercaptoethanol (BME,
Sigma), 100 U/mL penicillin, 100 μg/mL streptomycin
and 0.25 μg/mL amphotericin B. After 24 h, MSC were
cultured in induction medium consisting in DMEM
(high glucose) supplemented with 1 mM BME, 100 U/
mL penicillin, 100 μg/mL streptomycin and 0.25 μg/mL
amphotericin B. In protocol 2, MSC were cultured in a
pre-induction medium consisting in DMEM (high glu-
cose) supplemented with 20% FBS, 10 ng/mL bFGF (BD
Biosciences), 20 ng/mL EGF (BD Biosciences), 100 U/
mL penicillin, 100 μg/mL streptomycin and 0.25 μg/mL
amphotericin B. After 24 h, bMSC were cultured in in-
duction medium consisting in DMEM (high glucose)
supplemented with 200 μM BME, 25 mM KCL, 2 mM
valproic acid, 10 μM forskolin, 1% neural supplement
(N1) (All from Sigma), 100 U/mL penicillin, 100 μg/mL
streptomycin and 0.25 μg/mL amphotericin B. Cells
were cultured for a total period of 6 days at 38°C under
a humidified atmosphere containing 5% CO2. Medium
change was performed every other day and cell samples
were obtained from control and differentiation bMSC
at 0, 24, 96 and 144 h of culture and analyzed for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
NESTIN, MAP2, NGF, TRKA, PrPC gene expression.
Flow cytometry
The expression of CD29, CD34, CD45, CD73, OCT4
and NANOG was detected in bMSC using flow cytome-
try. Cells were removed from culture dishes using 5 mM
EDTA for 10 min at 38°C. Then cells were permeabilized
using a Foxp3 kit (eBioscience, San Diego, CA, USA) by
incubation at room temperature for 5 min with shaking.
Then cells were centrifuged at 2000 RPM for 5 min and
then in 2% normal rabbit serum in PBS. Then bMSC
were incubated in a 1:100 goat primary polyclonal anti-
body (CD34, CD73, OCT4 and NANOG; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) or rabbit primary
monoclonal antibody (CD29 and CD45; Santa Cruz Bio-
technology) for 30 min on ice with shaking. Then cells were
washed with PBS and centrifuged 2000 RPM for 5 min.
The pellet was resuspended in 1.5 mL of PBS and 1:100
donkey anti-goat or anti-mouse secondary antibodies
(Santa Cruz Biotechnology) and incubated for 30 min on
ice. After 3 washes on PBS, the pellet was resuspended on
cytometry buffer and analyzed using a FACS Calibur flow
cytometer (BD Bioscience) using a 488 nm (blue) and
633 nm (red) laser light. The signal was analyzed using a
Cellquest program (BD Bioscience). The threshold for
negative events was set on the first decade of fluorescence
level. Negative procedural control corresponded to replace-
ment of secondary antibody with non-immune serum.RNA extraction and cDNA synthesis
Cells were collected and immediately fixed in RLT buffer
(Qiagen, Incorporated, Valencia, CA, USA). Total RNA
was extracted using RNeasy Mini kit (Qiagen) following
manufacturer’s recommendations. The concentration and
purity of the RNA in each sample were determined using
spectrophotometry (BioRad Laboratories, Hercules, CA,
USA). Total RNA was eluted in 30–50 μL of RNase free
water. Samples were subjected to RT-PCR using Brilliant II
SYBR Green RT-PCR kit (Agilent). The reaction protocol
consisted of incubation for 5 min at 25°C, 15 min at 42°C,
5 min at 95°C and hold at 4°C using a DNA engine PCR
thermocycler (BioRad).
Quantitative-PCR
Real-time PCR primers were designed using PrimerEx-
press software (Applied Biosystems Incorporated, Foster
City, CA) (Table 1). Equivalence of amplification effi-
ciencies among all primer-probe sets was confirmed
using serial 3-fold dilutions of differentiated bMSC
cDNA. Each RT-PCR reaction (25 μL) contained the fol-
lowing: 2X Brilliant II SYBR Green QPCR master mix
(12.5 μL), diluted reference dye (0.375 μL), target for-
ward primer (200 nM), target reverse primer (200 nM),
cDNA synthesis reaction (2 μL) and nuclease-free PCR-
grade water to adjust final volume. The PCR amplifica-
tion was carried out in StepOne Real Time PCR System
(Applied Biosystems). Thermal cycling conditions were
95°C for 10 min, followed by 40 repetitive cycles at 95°C
for 30 sec and 60°C for 1 min. As a normalization con-
trol for RNA loading, parallel reactions in the same mul-
tiwell plate were performed using GAPDH or β-ACTIN
as a target. Quantification of gene amplification was
made following Q-PCR by determining the threshold
cycle (CT) number for SYBR fluorescence within the
geometric region of the semilog plot generated during
PCR. Within this region of the amplification curve, each
difference of one cycle is equivalent to a doubling of the
amplified product of the PCR. The relative quantification
of the target gene expression across treatment was eval-
uated using the comparative ΔΔCT method. The CT
value was determined by subtracting the most stable en-
dogenous gene CT value (β-ACTIN hepatogenesis; GAPDH,
neurogenesis) from the target CT value of the sample.
Calculation of ΔΔCT involved using target gene expression
on Day 0 (Sample with the highest CT value or lowest tar-
get expression) as an arbitrary constant to subtract from all
other CT sample values. Relative target mRNA expression
was calculated as fold changes in relation to Day or Hour 0
sample and expressed as 2-ΔΔCT value.
Immunofluorescence
Differentiated and control bMSC were fixed in a 4%
paraformaldehyde (PAF) for 10 min and permeabilized
Table 1 Sequence of primers used for Q-PCR analysis
Gene Sense Antisense Accession number
Housekeeping
GAPDH 5’ CCTTCATTGACCTTCACTACATGGTCTA 5’ TGGAAGATGGTGATGGCCTTTCCATTG NM 001034034.2
βACTIN 5’ CGCACCACTGGCATTGTCAT 5’ TCCAAGGCGACGTAGCAGAG K00622.1
Hepatogenic
AFP 5’ CTTGTTGCTTACACAAAGAAGG 5’ ATGGAAGATGAACTTGTCATCG NM 001034262.2
ALB 5’ TTTTCTCAGTATCTCCAGCAGT 5’ AGTAGGGATGTCTTCTAGCAAT NM 180992.2
α1AT 5’ GCTGGGGTTCTCCAAGGAC 5’ GTTTGCTCATTCACGTGGAAGTC NM 173882.2
CNX32 5’ ATGAACTGGACAGGTTTGTAC 5’ ATGTGTTGCTGGTGAGCCA NM 174069.2
CYP3A4 5’ ATCATTGCTGTCTCCAACCTTCAC 5’ TGCTTCCCGCCTCAGATTTCTC NM 001099367.1
TAT 5’ TTTGCTATGGAGCTTTGGCTGC 5’ AATGGTAGTGCAGCTCGCAGAA NM 001034590.1
Neurogenic
NESTIN 5’ CTGGAGCAGGAGAAACAAGG 5’ GAAAGGTTGGCACAGGTGTT NM 001206591.1
MAP2 5’ CCACCTGAGATTAAGGATCA 5’ GGCTTACTTTGCTTCTCTGA NM 001205807.1
NGF 5’ TCAACAGGACTCACAGGAGCAA 5’ ACCTCTCCCAGCACCATCAC NM 001099362.1
TRKA 5’ CTGGGTGAGGGTGCCTTT 5’ CGCTCTCAGACACCTCCTTCAG XM 002685965.3
PrPC 5’ CCAGAGACACAAATCCAACTTGAG 5’ AACCAGGATCCAACTGCCTATG NM 001271626.1
Pluripotency
NANOG 5’ GTGTTTGGTGAACTCTCCTG 5’ GGGAATTGAAATACTTGACAG NM 001025344.1
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rinsed twice in PBS and blocked in donkey serum
(Sigma) for 30 min at RT. Cells were incubated over-
night at 4°C with primary mouse monoclonal anti AFP
or PrPC antibody (1:50; Santa Cruz Biotechnology and
Cayman Chemical, Ann Arbor, MI) or primary goat
polyclonal anti NESTIN, MAP2, TRKA antibody (1:50;
Santa Cruz Biotechnology) diluted in donkey serum.
Then cells were rinsed three times with PBS and
incubated with goat anti-mouse or anti-goat IgG conju-
gated to FITC (1:200 in donkey serum) for 45 minutes.
Then cells were again rinsed three times in PBS and
mounted under coverslips in a solution containing 4’, 6-
diamidino-2-phenylindole (Santa Cruz Biotechnology).
Samples were examined under epifluorescence and the
results captured by digital photomicroscopy (Olympus,
Tokyo, Japan).Periodic Acid-Schiff (PAS)
Glycogen storage was evaluated in differentiated and
control bMSC using PAS staining. Culture dishes con-
taining cells were fixed in 4% paraformaldehyde for
10 min. Cells were rinsed 3 times in deionized (d) H2O
and treated with 0.5% periodic acid for 5 min at RT.
Then cells were rinsed 3 times in dH2O, treated with
Schiff ’s reagent for 15 minutes, and rinsed 3 times
in dH2O. Samples were counterstained with Mayer’shematoxylin for 1 minute and rinsed in dH2O and
assessed under light microscope.Urea assay
Urea concentrations were determined in media collected
from control and differentiated bMSC cultures by colori-
metric assay (Bioclin, Quibasa Quimica, Santa Branca,
Brazil) following manufacturer’s recommendations and
analyzed with spectrophotometer.Albumin assay
Albumin concentrations were determined in media col-
lected from control and differentiation MSC cultures by
Bromocresol green colorimetric assay (Biosystem, Barce-
lona, Spain) following manufacturer’s recommendations
and analyzed with spectrophotometer.Data analysis
Values of gene expression from four different replicates
were transferred to a spreadsheet and then analyzed
using Infostat software. Data was normalized to logarith-
mic scale in base 10 for normality and mean values for
each replicate were compared by one-way ANOVA.
Gene expression values between days of culture and be-
tween treatments and controls were analyzed using
Duncan’s multiple comparison test (P < 0.05).
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